Valuation: ExpreS2ion Biotech Holding AB

Market Cap 28.62M 2.9M 2.54M 2.38M 2.18M 4.08M 278M 4.08M 11.04M 142M 10.9M 10.66M 457M P/E 2026 *
-
P/E 2027 * -
Enterprise Value 28.62M 2.9M 2.54M 2.38M 2.18M 4.08M 278M 4.08M 11.04M 142M 10.9M 10.66M 457M EV / Sales 2026 *
0.94x
EV / Sales 2027 * -
Free-Float
99.89%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer - 2019-12-19
Director of Finance/CFO 50 2020-09-30
Chief Tech/Sci/R&D Officer - 2019-12-31
Director TitleAgeSince
Chairman 66 2009-12-31
Director/Board Member 58 2017-03-31
Director/Board Member 69 2021-05-25
Change 5-day change 1-year change 3-year change Capi.($)
+2.34%-2.28% - - 2.9M
+0.72%+3.85%+34.96%-2.54% 80.27B
+5.56%+26.98%+587.35%+82.58% 72.88B
-0.62%+2.87%-10.26%-29.08% 61.51B
-0.78%-1.49%-11.82%+28.69% 47.39B
+0.66%+1.72%+3.39%+159.99% 46.58B
+2.87%+4.25%+60.22%-12.54% 33.3B
+1.83%+4.26%+49.81%+118.47% 25.73B
+0.97%+10.52%+11.29%+166.67% 22.88B
+1.04%+1.96%+59.16%+103.91% 15.82B
Average +0.94%+6.00%+87.12%+68.46% 45.15B
Weighted average by Cap. +0.55%+7.38%+120.73%+51.49%

Financials

2026 *2027 *
Net sales 30.4M 3.08M 2.7M 2.53M 2.31M 4.34M 295M 4.34M 11.73M 151M 11.58M 11.33M 485M -
Net income - -
Net Debt - -
Logo ExpreS2ion Biotech Holding AB
ExpreS2ion Biotech Holding AB is a Sweden-based biopharmaceutical company. The Company specializes in developing cell lines and processes based on a non-viral Drosophila S2 cells expression system. The Company's ExpreS2 recombinant protein expression platform supports all phases of drug discovery, research and development and manufacturing. ExpreS2 is a non-viral insect cell expression system that establishes stable polyclonal pools that provide high-protein expression levels without selection pressure. The system is designed for transient or stable transfections using vector deoxyribonucleic acid containing a hybrid promoter. It also ensures high cell density without aggregation or toxic metabolite build-up issues. Through the joint venture AdaptVac ApS, the Company applies a Plug-and-Play Virus Like Particle technology for development of therapeutic and prophylactic vaccines within oncology, infectious diseases and immunological disorders.
Employees
-
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!